^
Association details:
| Biomarker: | NTRK1-TP53 fusion |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
490 - Rapid clinical response to Larotrectinib in a mCRC patient with a novel oncogenic NTRK1-TP53 fusion
Published date:
09/03/2020
Excerpt:
A 60-year old mCRC patient with obstructive colon cancer in the left flexur and multiple liver metastases,...NGS sequencing revealed the presence of a candidate gene fusion transcript: NTRK1-TP53 (Chr1:156843781-Chr17:7572360)...The patient started oral larotrectinib at 100 mg twice daily and has been enrolled in an observational registry trial (GASTRY) to monitor the effect of targeted therapy...Restaging CT scans, performed six weeks later, demonstrated a RECIST partial response. At this moment the patient is still on treatment and continues to be followed up with an ongoing PR and no significant treatment-related toxicities.
